World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 


U.S. Moves To Reduce Ebola Bioterrorism Threat

U.S. Disease Researchers Begin Ebola Vaccine Trial

Trial begins as new disease outbreak occurs in Republic of the Congo

A trial of the first experimental vaccine to prevent infection from the deadly Ebola virus began November 18 at the National Institute for Allergies and Infectious Diseases (NIAID) in Bethesda, Maryland.

The vaccine contains no infectious material from the Ebola virus, but was synthesized using modified, inactivated genes from the pathogen. According to a NIAID press release, 27 volunteers will be participating in the one-year trial in which researchers will seek to ascertain the safety of the vaccine.

The vaccine trial begins as the World Health Organization reported the occurrence of 11 cases of Ebola appearing in the Republic of the Congo November 17. Previous outbreaks in Africa have killed up to 90 percent of those infected. Considered one of the most deadly diseases known to medical science, Ebola' symptoms are a sudden onset of fever, weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhea, rash, limited kidney and liver functions, and both internal and external bleeding.

"An effective Ebola vaccine not only would provide a life-saving advance in countries where the disease occurs naturally, it also would provide a medical tool to discourage the use of Ebola virus as an agent of bioterrorism," said NIAID Director Anthony S. Fauci, M.D.

Following is the text of the NIAID press release:

(begin text)

National Institute of Allergy and Infectious Diseases
National Institutes of Health

Nov. 18, 2003

NIAID EBOLA VACCINE ENTERS HUMAN TRIAL

The first human trial of a vaccine designed to prevent Ebola infection opened today. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), designed the vaccine, which was administered to a volunteer at the NIH Clinical Center in Bethesda. The vaccine does not contain any infectious material from the Ebola virus.

Just three years ago, VRC Director Gary Nabel, M.D., Ph.D., together with a team of scientists from the VRC and the Centers for Disease Control and Prevention, described an experimental Ebola vaccine that fully protected monkeys from lethal infection by the virus. One component of that vaccine will now be assessed for safety in human volunteers. The trial vaccine, a type called a DNA vaccine, is similar to other investigational vaccines that hold promise for controlling such diseases as AIDS, influenza, malaria and hepatitis.

"This trial is further evidence of the ability of the VRC to rapidly translate basic research into tangible products," notes NIAID Director Anthony S. Fauci, M.D. "Our accelerated effort to understand and combat Ebola infection is part of the NIAID commitment to its biodefense mission. An effective Ebola vaccine not only would provide a life-saving advance in countries where the disease occurs naturally, it also would provide a medical tool to discourage the use of Ebola virus as an agent of bioterrorism."

Outbreaks of Ebola in Africa kill up to 90 percent of those infected. No effective treatment exists for this highly infectious disease, which causes extensive internal bleeding and rapid death. According to experts, vaccination is the best strategy for preventing or containing this deadly infection.

A gap of two decades separated the first Ebola epidemic of 1976 and the next, which arose in 1995. In recent years, for reasons unknown, outbreaks of Ebola are occurring with increasing frequency.

On November 17, 2003, the World Health Organization reported 11 cases of Ebola hemorrhagic fever in the Republic of the Congo. Dr. Nabel notes, "The current Ebola outbreak in the Congo provides a stark reminder of the need to rapidly develop vaccines against such perilous infections. A few years ago, we did not imagine that our vaccine would enter human trials so quickly, but the re-emergence of such viruses makes it all the more important to respond quickly. Individuals who volunteer for these vaccine trials can help us understand if our new vaccines ultimately will be effective."

Twenty-seven volunteers between the ages of 18 and 44 will participate in the study. Six people will receive a placebo injection and 21 will receive the investigational vaccine, manufactured by Vical Inc., a San Diego biotechnology company working in collaboration with the VRC. Vical has also secured a nonexclusive license from NIH to proprietary gene sequences used in the DNA Ebola vaccine. In the new trial, volunteers will receive three injections over two months and will be followed for one year. Volunteers will not be exposed to Ebola virus. Individuals interested in enrolling in the trial may visit http://www.clinicaltrials.gov or call the VRC toll-free at 1-866-833-LIFE (5433).

The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process, notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the VRC. "It is impossible for the vaccine to cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."

Besides assessing the vaccine's safety, researchers will also examine the volunteers' blood to look for signs of immune system reaction to the vaccine. Ultimately, the scientists envision this vaccine as the first in a two-stage vaccination strategy called prime-boost: after "priming" with the DNA vaccine, the immune system response is "boosted," or augmented, by a second inoculation with modified, non-disease-causing cold viruses that make selected Ebola proteins. The booster essentially sets the immune system on alert against future infection by Ebola virus.

In August, Dr. Nabel and his colleagues reported using the booster shot to quickly and completely protect monkeys against Ebola. A fast-acting vaccine would be of great use during an outbreak of Ebola. The full prime-boost strategy, which uses the DNA vaccine being tested in this study, elicits a stronger immune response and is important to pursue for individuals at high risk, such as health care workers. Dr. Nabel says that expanded human trials of Ebola vaccines using the prime-boost strategy could begin by 2005.

NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

### References: NJ Sullivan et al. Development of a protective vaccine for Ebola virus infection in primates. Nature 408:605-09 (2000). http://www.niaid.nih.gov/newsroom/releases/ebolavacc.htm N. Sullivan et al. Accelerated vaccine for Ebola virus hemorrhagic fever in non-human primates. Nature 424:681-84 (2003). http://www.niaid.nih.gov/newsroom/releases/ebolavaccine.htm

For a photo of the Ebola virus, go to http://www.niaid.nih.gov/cgi-shl/newsroom/newsrel.cfm and click on "NIAID Ebola Vaccine Enters Human Trial"

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at .


© Scoop Media

 
 
 
 
 
World Headlines

 

Myanmar Election: UNICEF Urges Prioritisation Of Children

With 99 days to go before Myanmar elections, UNICEF urges candidates make children the clear winner More>>

Liberia Thousands Of Unregistered Children Born During Ebola Crisis

Thousands of unregistered children born in Liberia during Ebola crisis at risk of exploitation – UNICEF More>>

UN Refugee Agency Envoy Angelina Jolie Visits Myanmar

UNHCR Special Envoy Angelina Jolie Pitt (left) in Myitkyina township, Kachin State, Myanmar, meeting with some of the 100,000 displaced people who currently live there. Photo: UNHCR/T.Stoddart More>>

As Health Needs Rise In Somalia, Funding Hits New Low

As health needs rise in Somalia, funding hits new low, cutting off 1.5 million from care – UN More>>

Need To End Violence Against Children In Conflict

‘We should be outraged’ more not being done to end violence against children in conflict – UNICEF chief More>>

On Mandela Day, UN Joins Call To Promote Community Service

Nelson Mandela, then Deputy President of the African National Congress of South Africa, raises his fist in the air while addressing the Special Committee Against Apartheid in the General Assembly Hall. UN Photo/P. Sudhakaran More>>

Some $3.2 Billion Needed For Ebola Recovery Efforts

Some $3.2 billion needed for Ebola recovery efforts in Guinea, Liberia and Sierra Leone – UN More>>

World Day: UN Spotlights Plight Of Vulnerable Populalations

Syrian refugees fleeing the fighting near the Syrian city of Kobani wait in a holding area before boarding buses in Turkey (September 2014). Photo: UNHCR /I. Prickett More>>

Afghanisatan: Direct Talks Between Government And Taliban

The United Nations Security Council has welcomed the recently held direct talks between Afghan Government and Taliban representatives as a step towards “peace and reconciliation” in the region. More>>

Eradicating World Hunger By 2030

Agriculture workers collect carrots on a farm in Chimaltenango, Guatemala. Photo: World Bank/Maria Fleischmann More>>

Bangladesh: Flood Leads To UN Agency Providing Food Relief

Anwar Hossain unloads cartons of High Energy Biscuits from a pickup truck and transfers them to a distribution center in Kawar Khop union, Ramu upazila, Cox’s Bazar, Bangladesh. Photo: WFP/Kamrul Mithon More>>

Get More From Scoop

 
 
 
 
 
World
Search Scoop  
 
 
Powered by Vodafone
NZ independent news